Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
Yun Hu, Sébastien Paris, Narayan Sahoo, Genevieve Bertolet, Qi Wang, Qianxia Wang, Hampartsoum B. Barsoumian, Jordan Da Silva, Ailing Huang, Denaha J. Doss, David P. Pollock, Ethan Hsu, Nanez Selene, Claudia S. Kettlun Leyton, Tiffany A. Voss, Fatemeh Masrorpour, Shonik Ganjoo, Carola Leuschner, Jordan T. Pietz, Nahum Puebla-Osorio, Saumil Gandhi, Quynh-Nhu Nguyen, Jing Wang, Maria Angelica Cortez, James W. Welsh
Yun Hu, Sébastien Paris, Narayan Sahoo, Genevieve Bertolet, Qi Wang, Qianxia Wang, Hampartsoum B. Barsoumian, Jordan Da Silva, Ailing Huang, Denaha J. Doss, David P. Pollock, Ethan Hsu, Nanez Selene, Claudia S. Kettlun Leyton, Tiffany A. Voss, Fatemeh Masrorpour, Shonik Ganjoo, Carola Leuschner, Jordan T. Pietz, Nahum Puebla-Osorio, Saumil Gandhi, Quynh-Nhu Nguyen, Jing Wang, Maria Angelica Cortez, James W. Welsh
View: Text | PDF
Research Article Therapeutics

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection

  • Text
  • PDF
Abstract

The combination of radiation therapy (RT) and immunotherapy has emerged as a promising treatment option in oncology. Historically, x-ray radiation (XRT) has been the most commonly used form of RT. However, proton beam therapy (PBT) is gaining recognition as a viable alternative, as it has been shown to produce similar outcomes to XRT while minimizing off-target effects. The effects of PBT on the antitumor immune response have only just begun to be described, and to our knowledge no studies to date have examined the effect of PBT as part of a combinatorial immunoradiotherapeutic strategy. Here, using a 2-tumor model of lung cancer in mice, we show that PBT in tandem with an anti-PD1 antibody substantially reduced growth in both irradiated and unirradiated tumors. This was accompanied by robust activation of the immune response, as evidenced by whole-tumor and single-cell RNA sequencing showing upregulation of a multitude of immune-related transcripts. This response was further significantly enhanced by the injection of the tumor to be irradiated with NBTXR3 nanoparticles. Tumors of mice treated with the triple combination exhibited increased infiltration and activation of cytotoxic immune cells. This triple combination eradicated both tumors in 37.5% of the treated mice and showed robust long-term immunity to cancer.

Authors

Yun Hu, Sébastien Paris, Narayan Sahoo, Genevieve Bertolet, Qi Wang, Qianxia Wang, Hampartsoum B. Barsoumian, Jordan Da Silva, Ailing Huang, Denaha J. Doss, David P. Pollock, Ethan Hsu, Nanez Selene, Claudia S. Kettlun Leyton, Tiffany A. Voss, Fatemeh Masrorpour, Shonik Ganjoo, Carola Leuschner, Jordan T. Pietz, Nahum Puebla-Osorio, Saumil Gandhi, Quynh-Nhu Nguyen, Jing Wang, Maria Angelica Cortez, James W. Welsh

×

Figure 8

Triple therapy of NBTXR3, PBT, and αPD1 induces antitumor memory immune response in mice.

Options: View larger image (or click on image) Download as PowerPoint
Triple therapy of NBTXR3, PBT, and αPD1 induces antitumor memory immune ...
(A) Tumor growth and the number of lung metastases in the survivor mice rechallenged with 344SQR cells. (B) Blood memory CD4+ and CD8+ T cells in the survivor mice before and after tumor rechallenge. (C) NanoString analysis of the blood immune cell populations 3 days before tumor rechallenge. The survivor mice treated with NBTXR3+PBT+αPD1 were rechallenged with 5 × 104 344SQR cells in the right flank 67 days after PBT, and the tumor growth was monitored. The memory immune status in the blood was profiled with flow cytometry 3 days before and 19 days after tumor rechallenge. The immune pathway activities in the blood were characterized by NanoString. The number of lung metastases was analyzed utilizing 2-tailed t tests. The percentages of blood memory CD4+ and CD8+ T cells were analyzed using either ordinary 1-way ANOVA or the Kruskal-Wallis test. Data are expressed as mean ± SEM. P < 0.05 was considered statistically significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. NS, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts